Table I.
Surgical and clinical-pathological characteristics of the series.
| Characteristics | N. (%) |
|---|---|
| Patients | 243 |
| Median Age, yrs (range) | 47 (25-80) |
| Radicality of Surgerya | |
| - Type A | 43 (17.7) |
| - Type B | 111 (45.7) |
| - Type C | 89 (36.6) |
| Lymph Node Surgery | |
| - Sentinel Lymph Node Biopsy | 47 (19.3) |
| - Pelvic Lymphadenectomy | 196 (80.7) |
| Aortic Lymphadenectomy | |
| - No | 159 (65.4) |
| - Yes | 84 (34.6) |
| Pathological FIGO stage | |
| - IA1 | 52 (21.4) |
| - IA2 | 15 (6.2) |
| - IB1 | 131 (53.9) |
| - IB2 | 8 (3.3) |
| - IIA1 | 9 (3.7) |
| - IIA2 | 5 (2.1) |
| - IIB | 23 (9.5) |
| Histology | |
| - Squamous carcinoma | 157 (64.6) |
| - Other | 86 (35.4) |
| Grading | |
| - G1 / G2 | 178 (73.3) |
| - G3 | 53 (21.8) |
| Tumor diameter | |
| - ≤ 20 mm | 157 (64.6) |
| - > 20 mm | 86 (35.4) |
| Lymphovascular space invasion | |
| - Absent | 154 (63.4) |
| - Present | 89 (36.6) |
| Lymph node status | |
| - Negative | 198 (81.5) |
| - Positive | 45 (18.5) |
| Adjuvant therapy | |
| - No | 140 (57.6) |
| - Radiotherapy | 46 (18.9) |
| - Chemotherapy | 4 (1.6) |
| - concomitant chemoradiotherapy | 53 (21.8) |
aaccording to Querleu and Morrow classifications